Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53: early-phase trial registry
A small indexed set (1 trial) with no open enrollment listed right now.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53: 1 US clinical trial tracked, none currently recruiting.
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Aprea Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition platinum-sensitive-recurrent-high-grade-serous-ovarian-cancer-with-mutated-p53
OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 is recruiting below its size-band peers.
0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 page
1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Aprea Therapeutics sponsors the most Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 trials on record, review their full trial history before evaluating a specific study. See Aprea Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 condition card totals 1 registered trials; most-linked intervention Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD); top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.